antibody

PLCE1 Antibody

MBS9418236

0.05 mL

200 USD

polyclonal

rabbit

nonconjugated

Antibody

PLCE1 Antibody

[PLCE1]

[1-phosphatidylinositol-4 antibody,5-bisphosphate phosphodiesterase epsilon-1 antibody, Pancreas-enriched phospholipase C antibody, Phosphoinositide phospholipase C-epsilon-1 antibody, Phospholipase C-epsilon-1 antibody, PLC-epsilon-1 antibody, Plce1 antibody, PLCE1_HUMAN antibody]

[1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1 isoform 2; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1; 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase epsilon-1; phospholipase C epsilon 1; Pancreas-enriched phospholipase C; Phosphoinositide phospholipase C-epsilon-1; Phospholipase C-epsilon-1; PLC-epsilon-1]

[PLCE1]

[PLCE1; PLCE1; PLCE; PPLC; NPHS3; KIAA1516; PLCE; PPLC; PLC-epsilon-1]

PLCE1_HUMAN

Polyclonal

Rabbit

Human

1994

PLCE1antibody detects endogenous levels of total PLCE1

Rabbit IgG in phosphate buffered saline, pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

1.0mg/mL

Store at -20°C

Western Blot (WB)

Western Blot: 1:500-1:2000

Western Blot (WB)

Immunogen Description: A synthesized peptide derived from human PLCE1. Immunogen Type: Peptide. Calculated MW: 259 kDa

Total protein Ab

260166694

NP_001159451.1

NM_001165979.2

Q9P212

AGE-RAGE Signaling Pathway In Diabetic Complications (1319988); AGE-RAGE Signaling Pathway In Diabetic Complications (1319775); Calcium Signaling Pathway (83050); Calcium Signaling Pathway (459); D-myo-inositol (1,4,5)-trisphosphate Biosynthesis Pathway (545326); D-myo-inositol (1,4,5)-trisphosphate Biosynthesis Pathway (138940); D-myo-inositol-5-phosphate Metabolism Pathway (545315); D-myo-inositol-5-phosphate Metabolism Pathway (138601); EGF/EGFR Signaling Pathway (198782); Inositol Phosphate Metabolism Pathway (82987)

This gene encodes a phospholipase enzyme that catalyzes the hydrolysis of phosphatidylinositol-4,5-bisphosphate to generate two second messengers: inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). These second messengers subsequently regulate various processes affecting cell growth, differentiation, and gene expression. This enzyme is regulated by small monomeric GTPases of the Ras and Rho families and by heterotrimeric G proteins. In addition to its phospholipase C catalytic activity, this enzyme has an N-terminal domain with guanine nucleotide exchange (GEF) activity. Mutations in this gene cause early-onset nephrotic syndrome; characterized by proteinuria, edema, and diffuse mesangial sclerosis or focal and segmental glomerulosclerosis. Alternative splicing results in multiple transcript variants encoding distinct isoforms.[provided by RefSeq, Sep 2009]

PLCE1: a widely expressed bifunctional enzyme with phospholipase activity and Ras guanine-exchange factor (RasGEF) activity. Catalyzes the release of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) from 1-phosphatidyl-1D-myo-inositol 4,5-bisphosphate. Is an effector of heterotrimeric G protein activation. May play a role in cell survival, cell growth, actin organization and T-cell activation. Activated by the heterotrimeric G-protein subunits GNA12, GNA13 and GNB1-GNG2. Activated by HRAS, RAP1A, RHOA, RHOB, RHOC, RRAS and RRAS2. Activated by the G(s)-coupled GPCRs ADRB2, PTGER1 and CHRM3 through cyclic-AMP formation and RAP2B activation. Inhibited by G(i)-coupled GPCRs. Interacts with RHOA. Interacts with IQGAP1, HRAS, RAP1A, RAP2A, RAP2B and RRAS. Recruited to plasma membrane by activated HRAS and RAP2. Recruited to perinuclear membrane by activated RAP1A. Requires calcium for activiation. The Ras-associating domain 1 is degenerate and may not bind HRAS. The Ras-associating domain 2 mediates interaction with GTP-bound HRAS, RAP1A, RAP2A and RAP2B and recruitment of HRAS to the cell membrane. The Ras-GEF domain has a GEF activity towards HRAS and RAP1A. Mediates activation of the mitogen-activated protein kinase pathway. Defects in PLCE1 are the cause of nephrotic syndrome type 3 (NPHS3). Nephrotic syndrome, a malfunction of the kidney glomerular filter, leads to proteinuria, hypoalbuminemia, edema. Overexpressed during heart failure. A GWAS study identified an association between esophageal squamous cell carcinoma and a common DNA variant in the PLCE1 gene in East Asians. Two isoforms of the human protein are produced by alternative splicing. Isoform 1 is broadly expressed and only absent in peripheral blood leukocytes. Isoform 2 is specifically expressed in placenta, lung and spleen. Isoform 1 and isoform 2 associate with Golgi membranes. Protein type: Carbohydrate Metabolism - inositol phosphate; EC 3.1.4.11; GAPs; GAPs, Ras; Phospholipase. Chromosomal Location of Human Ortholog: 10q23. Cellular Component: cytoplasm; cytosol; plasma membrane. Molecular Function: enzyme binding; guanyl-nucleotide exchange factor activity; phosphoinositide phospholipase C activity; phospholipase C activity; protein binding; Ras GTPase binding; receptor signaling protein activity. Biological Process: activation of MAPK activity; calcium-mediated signaling; diacylglycerol biosynthetic process; elevation of cytosolic calcium ion concentration; G-protein signaling, coupled to IP3 second messenger (phospholipase C activating); glomerulus development; heart development; inositol phosphate metabolic process; inositol phosphate-mediated signaling; phospholipid metabolic process; Ras protein signal transduction; regulation of cell growth; regulation of G-protein coupled receptor protein signaling pathway; regulation of protein kinase activity; regulation of Ras protein signal transduction; regulation of smooth muscle contraction. Disease: Nephrotic Syndrome, Type 3

0.05 mL

200 USD

0.1 mL

255